This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Using the Canary Breathing System for Panic Disorder Patients

This study has been completed.
Information provided by (Responsible Party):
Palo Alto Health Sciences, Inc. Identifier:
First received: September 30, 2013
Last updated: January 12, 2017
Last verified: January 2017
The purpose of this study is to test the effectiveness of the Canary Breathing System (CBS) in treating the symptoms of panic disorder.

Condition Intervention Phase
Panic Disorder Device: Canary Breathing System Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigation of the Canary Breathing System for Treating the Symptoms of Panic Disorder

Resource links provided by NLM:

Further study details as provided by Palo Alto Health Sciences, Inc.:

Primary Outcome Measures:
  • Score on the Panic Disorder Severity Scale [ Time Frame: Measured at 2 months past the last intervention. ]

Enrollment: 69
Study Start Date: September 2013
Study Completion Date: May 2016
Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Canary Breathing System Device: Canary Breathing System
The Canary Breathing System is a biofeedback device meant to assist patients in the re-training of normal breathing patterns.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary diagnosis of Panic Disorder
  • Subjects between 18 and 60 years of age (inclusive on day of enrollment)
  • Subjects with a Clinician's Global Impression of > or = to 4.
  • If on psychotropic medication, on a stable dose for a minimum of 3 months prior to enrollment
  • If on psychotropic medication, an agreement to stay on their stable dose from study entry until the 2-month follow-up.

Exclusion Criteria:

  • Pregnancy
  • Current enrollment in another drug or device study
  • Current enrollment in another drug or device study that is not at least 30 days past the final follow-up
  • Currently undergoing cognitive behavioral therapy (or equivalent)
  • Refractory to either a breathing training program or cognitive behavioral therapy (or equivalent) in the 3 months prior to enrollment
  • Evidence of organic mental disorder
  • Severe suicidality
  • Presence of any psychotic disorder
  • Bipolar disorder that is present for < 5 years; a major depressive, manic or hypomanic episode in the last 12 months; failure to take and maintain a stable dose of medication in treatment of bipolar disorder in the last 12 months
  • Current alcohol or drug dependence
  • Cardiovascular or pulmonary disease
  • Epilepsy or seizures
  • Undergoing additional psychologic treatment at any point from study enrollment to 2-month follow-up to treat panic disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01955954

United States, California
San Francisco Bay Area Center for Cognitive Therapy
Oakland, California, United States, 94618
United States, Connecticut
Institute of Living
Hartford, Connecticut, United States, 06106
United States, Illinois
Alexian Brothers Center for Anxiety and OCD
Hoffman Estates, Illinois, United States, 60169
United States, Kansas
Kansas City Center for Anxiety Treatment, P.A.
Overland Park, Kansas, United States, 66212
Sponsors and Collaborators
Palo Alto Health Sciences, Inc.
  More Information

Responsible Party: Palo Alto Health Sciences, Inc. Identifier: NCT01955954     History of Changes
Other Study ID Numbers: PAHS 1-001-13
Study First Received: September 30, 2013
Last Updated: January 12, 2017

Keywords provided by Palo Alto Health Sciences, Inc.:
carbon dioxide monitoring
panic disorder
breathing training
Primary diagnosis

Additional relevant MeSH terms:
Respiratory Aspiration
Panic Disorder
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Anxiety Disorders
Mental Disorders processed this record on August 18, 2017